However, the molecular mechanism is not completely understood and future studies are warranted to clarify it and to assess the utility of FOXC1 as a potential cancer biomarker of induction chemotherapy outcome to improve risk-stratification of AML. This evidence concerns the gene FOXC1 and acute myeloid leukemia.